Kns-760704 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 16 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-006119-70-DE (EUCTR) | 31/08/2012 | 20/06/2012 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Other descriptive name: Dexpramipexole | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 850 | United States;Canada;Belgium;Spain;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden | |||
| 2 | EUCTR2011-006119-70-NL (EUCTR) | 30/08/2012 | 14/06/2012 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Other descriptive name: Dexpramipexole | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 850 | United States;Canada;Belgium;Spain;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | |||
| 3 | EUCTR2011-006119-70-BE (EUCTR) | 13/08/2012 | 14/06/2012 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Other descriptive name: Dexpramipexole | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 850 | Phase 3 | United States;Canada;Spain;Belgium;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | ||
| 4 | EUCTR2011-006119-70-GB (EUCTR) | 10/08/2012 | 18/06/2012 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Other descriptive name: Dexpramipexole | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 850 | United States;Canada;Belgium;Spain;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | |||
| 5 | EUCTR2011-006119-70-IE (EUCTR) | 03/08/2012 | 07/06/2012 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Other descriptive name: Dexpramipexole | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 850 | United States;Canada;Belgium;Spain;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2011-006119-70-ES (EUCTR) | 27/07/2012 | 11/06/2012 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Other descriptive name: Dexpramipexole | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 850 | United States;Canada;Belgium;Spain;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | |||
| 7 | EUCTR2011-006119-70-SE (EUCTR) | 15/05/2012 | 19/04/2012 | Clinical Extension Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis - ENVISION | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050/KNS-760704 Other descriptive name: Dexpramipexole | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 850 | United States;Canada;Belgium;Spain;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | |||
| 8 | EUCTR2010-022818-19-ES (EUCTR) | 09/06/2011 | 21/02/2011 | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de la seguridad y eficacia de Dexpramipexol en sujetos con Esclerosis Lateral Amiotrófica - EMPOWER | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de la seguridad y eficacia de Dexpramipexol en sujetos con Esclerosis Lateral Amiotrófica - EMPOWER | Amyotrophic lateral sclerosis (ALS)Esclerosis lateral amiotrófica (ELA) MedDRA version: 12.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 804 | Germany;United Kingdom;Netherlands;Ireland;Spain;Sweden | |||
| 9 | EUCTR2010-022818-19-BE (EUCTR) | 07/06/2011 | 24/01/2011 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | Amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: Dexpramipexole Dichydrochloride Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Not Recruiting | Female: yes Male: yes | 915 | Phase 3 | United States;Canada;Spain;Belgium;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden | ||
| 10 | EUCTR2010-022818-19-NL (EUCTR) | 24/05/2011 | 11/05/2011 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | Amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: Dexpramipexole Dichydrochloride Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Not Recruiting | Female: yes Male: yes | 915 | United States;Canada;Spain;Ireland;Australia;Germany;Netherlands;United Kingdom;Sweden | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2010-022818-19-DE (EUCTR) | 12/05/2011 | 21/02/2011 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | Amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: Dexpramipexole Dihydrochloride Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Not Recruiting | Female: yes Male: yes | 915 | United States;Canada;Spain;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden | |||
| 12 | EUCTR2010-022818-19-IE (EUCTR) | 08/04/2011 | 15/02/2011 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | Amyotrophic lateral sclerosis (ALS) MedDRA version: 15.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: Dexpramipexole Dichydrochloride Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Not Recruiting | Female: yes Male: yes | 915 | United States;Canada;Spain;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden | |||
| 13 | EUCTR2010-022818-19-SE (EUCTR) | 07/04/2011 | 09/02/2011 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | Amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: Dexpramipexole Dichydrochloride Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Not Recruiting | Female: yes Male: yes | 915 | Spain;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden;United States;Canada | |||
| 14 | EUCTR2010-022818-19-GB (EUCTR) | 22/03/2011 | 10/01/2011 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: Dexpramipexole Dichydrochloride Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Not Recruiting | Female: yes Male: yes | 915 | United States;Canada;Spain;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden | |||
| 15 | NCT00931944 (ClinicalTrials.gov) | July 2009 | 30/6/2009 | Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211) | An Open-Label, Safety and Tolerability, Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: KNS-760704 | Knopp Biosciences | NULL | Completed | 21 Years | 80 Years | All | 74 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00647296 (ClinicalTrials.gov) | March 2008 | 26/3/2008 | Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) | A 2-Part, Randomized, Double-Blind, Safety and Tolerability Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: KNS-760704;Drug: Placebo | Knopp Biosciences | NULL | Completed | 21 Years | 80 Years | All | 102 | Phase 2 | United States |